Characteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Center

Imagem de Miniatura
Arquivos
art_MARCONDES-BRAGA_Characteristics_and_Outcomes_of_Heart_Transplant_Recipients_With_2022.PDF (460.03 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
MURAD, Ciro M.
Citação
TRANSPLANTATION, v.106, n.3, p.641-647, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Heart transplant (HT) recipients may be at higher risk of acquiring SARS-CoV-2 infection and developing critical illness. The aim of this study is to describe characteristics and outcomes of HT recipients infected by SARS-COV-2, from a high-volume transplant center. Methods. We have described data of all adult HT recipients with confirmed coronavirus disease 2019 by RT-PCR in nasopharyngeal samples from April 5, 2020, to January 5, 2021. Outcomes and follow-up were recorded until February 5, 2021. Results. Forty patients were included. Twenty-four patients (60%) were men; the median age was 53 (40-60) y old; median HT time was 34 mo; and median follow-up time 162 d. The majority needed hospitalization (83%). Immunosuppressive therapy was reduced/withdrawn in the majority of patients, except from steroids, which were maintained. Seventeen patients (42.5%) were classified as having severe disease according to the ordinal scale developed by the World Health Organization Committee. They tended to have lower absolute lymphocyte count (P < 0.001) during follow-up when compared with patients with mild disease. Thirty-day mortality was 12.5%. However, a longer follow-up revealed increased later mortality (27.5%), with median time to death around 35 d. Bacterial nosocomial infections were a leading cause of death. Cardiac allograft rejection (10%) and ventricular dysfunction (12.5%) were also not negligible. Conclusions. Major findings of this study corroborate other cohorts' results, but it also reports significant rate of later events, suggesting that a strict midterm surveillance is advisable to HT recipients with coronavirus disease 2019.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/46227
Referências
  1. Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
  2. Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
  3. Ali T, 2021, TRANSPLANTATION, V105, P121, DOI 10.1097/TP.0000000000003433
  4. Avery RK, 2021, TRANSPLANTATION, V105, P56, DOI 10.1097/TP.0000000000003519
  5. Azzi Y, 2021, TRANSPLANTATION, V105, P37, DOI 10.1097/TP.0000000000003523
  6. Bottio T, 2021, JACC-HEART FAIL, V9, P52, DOI 10.1016/j.jchf.2020.10.009
  7. Buetti N, 2021, INTENS CARE MED, V47, P180, DOI 10.1007/s00134-021-06346-w
  8. Caillard S, 2020, KIDNEY INT, V98, P1549, DOI 10.1016/j.kint.2020.08.005
  9. Chapman JR, 2021, TRANSPLANTATION, V105, P1, DOI 10.1097/TP.0000000000003544
  10. Clancy CJ, 2020, JAC-ANTIMICROB RESIS, V2, DOI 10.1093/jacamr/dlaa049
  11. Coll E, 2021, AM J TRANSPLANT, V21, P1825, DOI 10.1111/ajt.16369
  12. Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
  13. Cravedi P, 2020, AM J TRANSPLANT, V20, P3140, DOI 10.1111/ajt.16185
  14. Crespo M, 2020, AM J TRANSPLANT, V20, P2883, DOI 10.1111/ajt.16096
  15. Felldin M, 2021, TRANSPLANTATION, V105, P108, DOI 10.1097/TP.0000000000003436
  16. Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
  17. Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]
  18. Kates Olivia S, 2021, Clin Infect Dis, V73, pe4090, DOI 10.1093/cid/ciaa1097
  19. Kutzler HL, 2021, TRANSPLANTATION, V105, pE6, DOI 10.1097/TP.0000000000003495
  20. Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016
  21. Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
  22. Lee K, 2009, GLOB INST, P1
  23. Li J, 2021, J MED VIROL, V93, P1449, DOI 10.1002/jmv.26424
  24. Ministerio da Saude, 2021, PAIN COR
  25. Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
  26. Rivinius R, 2020, CLIN RES CARDIOL, V109, P1531, DOI 10.1007/s00392-020-01722-w
  27. Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
  28. Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
  29. WHO R&D Blueprint, 2020, NOV COR COVID 19 THE
  30. Yi SG, 2020, TRANSPLANTATION, V104, P2208, DOI 10.1097/TP.0000000000003339
  31. Zaidan M, 2021, TRANSPLANTATION, V105, P61, DOI 10.1097/TP.0000000000003536
  32. Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
  33. Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - LIM/47
Artigos e Materiais de Revistas Científicas - ODS/03